Gold-standard clinical trials fail to capture how behavior changes influence treatment

(Princeton University, Woodrow Wilson School of Public and International Affairs) Double-blind clinical trials for new drugs are considered the 'gold standard' of medical research but one effect these trials fail to measure is how a medication's performance can vary based on patients' lifestyle choices, according to a new study in PLOS ONE. Researchers from Princeton University, the California Institute of Technology and Cambridge University propose a new trial design that can measure such interactions between behavior and treatment.
Source: EurekAlert! - Medicine and Health - Category: Global & Universal Source Type: news